These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1573 related items for PubMed ID: 19433689

  • 1. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K.
    J Clin Oncol; 2009 Jun 20; 27(18):2924-30. PubMed ID: 19433689
    [Abstract] [Full Text] [Related]

  • 2. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 3. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ.
    J Urol; 2003 Nov 01; 170(5):1860-3. PubMed ID: 14532793
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D, Loewen H, Roggenbuck U, Musch M, Klevecka V.
    BJU Int; 2006 May 01; 97(5):985-91. PubMed ID: 16643480
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression].
    Bolla M, Van Poppel H, Collette L, au nom des groupes génito-urinaire et radiothérapie de l'EORTC.
    Cancer Radiother; 2007 Nov 01; 11(6-7):363-9. PubMed ID: 17931949
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up after triple treatment of prostate cancer stage pT3.
    Schelin S, Madsen M, Palmqvist E, Mäkelä E, Klintenberg C, Aus G.
    Scand J Urol Nephrol; 2009 Nov 01; 43(3):186-91. PubMed ID: 19353383
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Cancer; 2002 Jul 15; 95(2):281-6. PubMed ID: 12124827
    [Abstract] [Full Text] [Related]

  • 11. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR, Presti JC, Gill H, Brooks J, Hancock SL.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):341-7. PubMed ID: 15145146
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H.
    J Urol; 2002 Jan 01; 167(1):117-22. PubMed ID: 11743287
    [Abstract] [Full Text] [Related]

  • 14. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H.
    BJU Int; 2005 Apr 01; 95(6):751-6. PubMed ID: 15794776
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer.
    Valicenti RK, Chervoneva I, Gomella LG.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1093-7. PubMed ID: 15001249
    [Abstract] [Full Text] [Related]

  • 18. Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.
    Krygiel JM, Smith DS, Homan SM, Sumner W, Nease RF, Brownson RC, Catalona WJ.
    J Urol; 2005 Jul 15; 174(1):126-30. PubMed ID: 15947596
    [Abstract] [Full Text] [Related]

  • 19. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer.
    Sasaki T, Nakamura K, Shioyama Y, Ohga S, Toba T, Urashima Y, Yoshitake T, Terashima H, Koga H, Naito S, Noma H, Komatsu K, Yamaguchi A, Hiratsuka Y, Hirano T, Hanada K, Abe M, Fujisawa Y, Honda H.
    Anticancer Res; 2006 Jul 15; 26(3B):2367-74. PubMed ID: 16821618
    [Abstract] [Full Text] [Related]

  • 20. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
    Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, Slawin K, Scardino PT.
    J Urol; 2005 Sep 15; 174(3):903-7. PubMed ID: 16093984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.